US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Finding the big picture for Alzheimer’s

The $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’ approach to th

A bright future for CNS and Alzheimer's?

Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare CNS condition that can impair balance, movement, vision, and sp

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (C

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of spinout biotech Cerevel Therapeutics.

Tysabri failure in stroke a setback for Biogen

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.